权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

Human Phenotyping Core

人类表型核心

基本信息

批准号：
10016171
负责人：
Joel Marvin Guthridge
金额：
$ 36.85万
依托单位：
OKLAHOMA MEDICAL RESEARCH FOUNDATION
依托单位国家：
美国
项目类别：
财政年份：
2018
资助国家：
美国
起止时间：
2018-09-07 至 2023-08-31
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/10016171
关键词：
Address Autoantibodies Autoimmune Diseases Biological Assay Biological Markers Blood Cells Caring Cells Characteristics Clinical Competence Complex Consultations Data Data Analyses Data Set Databases Development Diagnostic Disease Effectiveness Ensure Epigenetic Process Equipment Experimental Designs Flow Cytometry Foundations Freezing Funding Future Generations Genetic Genetic Polymorphism Genomic DNA Genomics Genotype Human Human Herpesvirus 4 Human Resources Immune Immunologics Immunophenotyping Individual Inflammatory Investigation Knowledge Measures Mediator of activation protein Methodology Methods Molecular Molecular Profiling Oklahoma Pathogenesis Pathway interactions Patients Phenotype Plasma Population Preparation Process Proteomics Quality Control Reproducibility Research Research Personnel Resources Rheumatism Sampling Serum Services Site Specimen Statistical Models System Technical Expertise Technology Therapeutic Time Transformed Cell Line Variant base biobank chemokine clinical center clinical phenotype clinically relevant computerized data processing cytokine data quality design experience experimental study human disease immune function molecular phenotype novel novel strategies phenotypic data precision medicine prognostic tool programs response single-cell RNA sequencing success transcriptome transcriptomics

项目摘要

Human Phenotyping Core Project Summary The rapid development of new approaches to interrogate the immune and inflammatory systems comes with a growing demand for both technical and conceptual expertise in these methodologies. The Human Phenotyping Core was created to support these activities within the Oklahoma Rheumatic Disease Resources Cores Center (ORDRCC). To address the most broadly scientifically interesting and clinically important questions, our ORDRCC Investigators need access to cutting-edge approaches, such as scRNA-Seq/CITE- Seq, ChipCytometry, and CyTOF to perform incisive experiments and to generate high-quality, reproducible data. The Human Phenotyping Core will allow our investigators to ask novel questions regarding the molecular phenotypes of rheumatic diseases. In addition to providing ORDRCC investigators with high-content biomolecular phenotyping services, the Human Phenotyping Core in conjunction with the Clinical Characterization and Biorepository Core (CCBC) will provide access to datasets containing previously collected genetic, proteomic, and biomolecular phenotypes of clinical subjects whose samples are available from the CCBC. The tight integration of the Human Phenotyping Core, CCBC and our databases will enable investigators to efficiently phenotype samples and correlate molecular and cellular phenotypes with clinical characteristics, to select more homogeneous patients for hypothesis-driven investigation and help provide the foundational knowledge needed for precision medicine in rheumatic disease care. By consolidating a range of technologies required for the complete characterization of molecular or cellular phenotypes into a single unit, the Human Phenotyping Core (HPC) will streamline services to help ORDRCC investigators in the efficient planning, design, execution and data analysis required for their individual projects. The HPC will provide experience in performing research using clinical specimens, technical expertise in a wide range of molecular and bioassays, access to equipment and resources thus enabling cutting-edge approaches to address research questions, quality control assessment of the data collected and data processing suitable for higher end statistical modeling of phenotype/clinical associations. SPECIFIC AIM 1: Assist ORDRCC Investigators, JCIs and Scholars to navigate the stages of project development, experimental design, resource planning and execution of translational and mechanistic studies through Core Management and individual consultations. SPECIFIC AIM 2: Provide access to advanced molecular phenotyping technologies and experienced technical personnel for efficient execution of advanced experimental data plans. SPECIFIC AIM 3: Establish processes to ensure data quality control, processing of raw data, and preparation of data sets for more extensive analysis and statistical modeling. SPECIFIC AIM 4: Evaluate, assess and implement new cutting-edge technologies for molecular phenotyping.

人类表型核心项目摘要研究免疫和炎症系统的新方法迅速发展对这些方法的技术和概念专业知识的需求不断增长。人类创建表型核心是为了支持俄克拉荷马州风湿病资源内的这些活动核心中心（ORDRCC）。解决最广泛的科学兴趣和临床重要性问题，我们的 ORDRCC 研究人员需要使用尖端方法，例如 scRNA-Seq/CITE- Seq、ChipCytometry 和 CyTOF 可进行深入的实验并生成高质量、可重复的实验数据。人类表型核心将使我们的研究人员能够提出有关分子的新问题风湿性疾病的表型。除了为 ORDRCC 调查人员提供高内容生物分子表型分析服务，人类表型分析核心与临床表征和生物库核心（CCBC）将提供对包含先前内容的数据集的访问收集可获得样本的临床受试者的遗传、蛋白质组和生物分子表型来自 CCBC。人类表型核心、CCBC 和我们的数据库的紧密集成将使研究人员能够有效地对样本进行表型分析，并将分子和细胞表型与临床相关联特征，选择更多同质的患者进行假设驱动的调查，并帮助提供风湿病护理精准医学所需的基础知识。通过整合分子或分子的完整表征所需的一系列技术将细胞表型整合为一个单元，人类表型核心 (HPC) 将简化服务以帮助 ORDRCC 调查人员进行其所需的高效规划、设计、执行和数据分析个人项目。 HPC 将提供使用临床标本进行研究的经验，广泛的分子和生物测定方面的技术专长，从而获得设备和资源启用尖端方法来解决研究问题、数据的质量控制评估收集和数据处理适合表型/临床关联的高端统计模型。具体目标 1：协助 ORDRCC 调查员、JCI 和学者了解项目的各个阶段转化和机制研究的开发、实验设计、资源规划和执行通过核心管理和个人咨询。具体目标 2：提供先进的分子表型技术和经验丰富的机会技术人员高效执行先进的实验数据计划。具体目标 3：建立流程以确保数据质量控制、原始数据处理和准备数据集以进行更广泛的分析和统计建模。具体目标 4：评估、评估和实施分子表型分析的新尖端技术。